

Neonatal sepsis due to non-*albicans* *Candida* species and their susceptibility to antifungal agents: first report from Bangladesh

Rafia Afreen Jalil^{1*}, K.M. Shahidul Islam², Lovely Barai², Shahida Akhter³

¹Department of Microbiology, Green Life Medical College, Green Road, Dhaka, Bangladesh,

²Department of Microbiology, BIRDEM General Hospital, Shahbag, Dhaka, Bangladesh,

³Department of Neonatology, BIRDEM General Hospital-2, Segunbagicha, Dhaka, Bangladesh

Abstract

Background and objectives: Frequency of neonatal sepsis in Neonatal Intensive Care Units (NICU) has been increasing worldwide over the last decades. The emergence of non-*albicans* *Candida* (NAC) species and their resistance to common antifungal agents become an important preventive and therapeutic issue. The present study was undertaken to find out the role of NAC species in neonatal sepsis/candidemia in the NICUs of hospitals of Dhaka city. The susceptibility pattern of NAC species to antifungal agents was also determined.

Materials and methods: Suspected cases of neonatal sepsis admitted in NICU of four tertiary care hospitals of Dhaka city, from March to December 2018 were enrolled. In this cross sectional study, blood samples were collected from neonates with suspected sepsis for culture. Identification of *Candida* species was done by carbohydrate (CHO) assimilation tests using swab auxanographic technique, CHO impregnated yeast nitrogen base plate method (YNB), microtiter plate based miniaturized method and by HiCrome™ *Candida* Differential Media. Susceptibility of the isolated *Candida* species to antifungal agents was determined by disk diffusion (DD) and by minimum inhibitory concentration (MIC) methods. MIC was determined by broth microdilution method using RPMI 1640 and trypticase soy broth (TSB).

Results: In the present study, NAC species were isolated from 39.7% neonates. *C. tropicalis* was the predominant species (81.0%) followed by *C. parapsilosis* (12.1%), *C. auris* (5.2%) and *C. dubliniensis* (1.7%). Isolated NAC species were 98.3% sensitive to voriconazole. Sensitivity to fluconazole, ketoconazole, itraconazole, and clotrimazole was 3.5%, 15.5%, 86.2% and 56.9% respectively by DD method. All the isolates (100%) were sensitive to miconazole and nystatin. All the *C. tropicalis*, *C. auris* and *C. dubliniensis* were sensitive to amphotericin B and anidulafungin. One and four *C. parapsilosis* were found resistant to amphotericin B and anidulafungin respectively. The MIC results obtained by using RPMI 1640 and TSB as growth medium were concordant suggesting that TSB media was a good alternative to expensive RPMI 1640.

Conclusion: The advent of NAC species merits attention as they are highly resistant to most of the azoles. Therefore, speciation of *Candida* in neonatal candidemia is essential to institute appropriate antifungal therapy.

IMC J Med Sci 2020; 14(2): 005. DOI: <https://doi.org/10.3329/imcjms.v14i2.52827>

Introduction

Over the last two decades, blood stream infection (BSI) by *Candida* species has become a significant issue in neonatal intensive care units (NICUs).

Candidemia is the third most common cause of late onset sepsis in neonates. It is responsible for 9-13% of BSI in neonates and is associated with high crude and attributable mortality rates [1].

*Correspondence: Rafia Afreen Jalil, Department of Microbiology, Green Life Medical College, Green Road, Dhaka, Bangladesh. Email: rafiaafreen133@gmail.com

Among the *Candida* species, *C. albicans* is the most commonly isolated organism. But recently non-*albicans Candida* (NAC) species have emerged as potential pathogens, particularly *C. tropicalis*, *C. parapsilosis*, *C. krusei*, *C. glabrata* and *C. auris* [2-4]. Various factors such as broad spectrum antibiotics, indwelling devices, prematurity, low birth weight (LBW), total parenteral nutrition (TPN), artificial ventilation and gastrointestinal surgery contribute to the risk of fungal colonization and infection. Also, fungal colonization is associated with overcrowding in the NICU, inadequate nurse-to-patient ratio and poor hygiene practices. Approximately 10% of the newborns are colonized during the first week of life and up to 64% of them get colonized by 4 weeks stay in hospital [5-6]. *Candida* species may spread via vertical transmission from the maternal flora or by horizontal transmission from the healthcare workers (HCW) hands [7-8].

Majority of the *Candida* species become resistant to the antifungal agents, mainly to triazole compounds, by the expression of efflux pumps that minimize drug accumulation, altering the structure or concentration of antifungal target proteins and modification of membrane sterol composition [9,10]. Some NAC species are intrinsically resistant to fluconazole and newer triazoles. Therefore, speciation and antifungal susceptibility of all the yeast isolates are essential. Owing to significant regional heterogeneity, local epidemiological data is crucial in the prevention and management of invasive candidiasis.

No study has yet been carried out in Bangladesh on the frequency and the types of NAC species responsible for sepsis in neonates admitted at the NICUs of different hospitals. The present study was undertaken to determine the NAC species and their antifungal susceptibility pattern causing neonatal sepsis in the NICUs of four tertiary care hospitals of Dhaka city.

Materials and methods

This cross sectional hospital based study was carried out in the Department of Microbiology, Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders

(BIRDEM) in collaboration with Department of Neonatology of four tertiary care hospitals of Dhaka city. The study period was from March, 2018 to December, 2018. The study was approved by the Institutional Ethical Committee of each institution and written informed consents from patients' guardian were obtained prior to collection of samples.

Study population and collection of blood samples:

Neonates admitted in respective NICUs with suspected septicemia were included in the study. About 1-2 ml of peripheral venous blood samples were collected aseptically from enrolled neonates. Immediately, 0.5-1 ml of blood was inoculated in BacT/Alert PF plus bottle and remaining 0.5-1 ml blood inoculated in the lytic blood culture tube. The specimens were transported immediately to microbiology laboratory of BIRDEM. Since *Candida* could be part of skin flora of neonates admitted in hospital, its isolation from blood culture might reflect contamination from skin flora. To rule out this contamination, a second blood sample was collected from the culture positive cases.

Candidemia was diagnosed by isolation of *Candida* species from at least two consecutive blood samples with clinical features of septicemia.

Isolation and identification of NAC species: Culture was performed using standard microbiological techniques [11,12]. *Candida* was identified by colony morphology, wet film and Gram stain. Species identification was done by germ tube test, carbohydrate (CHO) assimilation tests using swab auxanographic technique, carbohydrate impregnated yeast nitrogen base plate method and microtitre plate based miniaturized method, modified enrichment broth growth assay and HiCrome™ *Candida* Differential Media [13-16]. Yeast nitrogen base, bromocresol purple and eleven types of carbohydrates were used in all the three methods of CHO assimilation tests. In swab auxanographic method, carbohydrate was incorporated in individual discs. In the microtitre plate and CHO impregnated YNB plate methods, the carbohydrates were incorporated in the media. Growth in the media and turning the bromocresol purple to yellow indicated utilization of particular

carbohydrate. *C. auris* was further confirmed by modified enrichment broth growth assay with salt yeast nitrogen base broth. Growth at 42°C and development of a yellow colour in the medium indicated *C. auris*. The *Candida* isolates were inoculated on HiCrome™ *Candida* Differential Media and incubated at 37°C for 24 hours and the species were identified by colour of the colonies as per manufacturer's instructions.

Antifungal susceptibility tests: Antifungal susceptibility test was performed by disk diffusion method using Mueller-Hinton agar supplemented with 2% glucose and 0.5 µg/ml methylene blue dye. Inhibition zones for fluconazole and voriconazole were interpreted according to validated CLSI (M44-A) [17], while for other drugs the inhibition zones were adopted from published studies [18-20]. Broth microdilution was done to determine minimum inhibitory concentration (MIC) of fluconazole, amphotericin B and anidulafungin as per NCCLS M27-A2 and EUCAST v 7.3.1 [21,22] using both RPMI 1640 and trypticase soy broth as growth medium. For determination of minimal fungicidal concentration (MFC), 2 µl of broth was withdrawn from the optically clear MIC well of respective antifungal agent (concentrations above the MIC) and plated on Sabouraud dextrose agar plate and incubated at 35°C for 72 hrs. MFC was defined as the lowest drug concentration that yielded less than three colonies, a killing activity of ~ 99% [23].

Results

A total of 146 neonates with suspected sepsis were enrolled in the study. Out of 146 suspected cases of neonatal sepsis, 91 (62.3%) yielded positive blood culture. NAC species was isolated from 58 (39.7%) cases and remaining 33 (22.6%) yielded growth of bacteria (Table-1). Detail rate of isolation of NAC species from different categories of study population is shown in Table-1. Rate of isolation of NAC species from term and preterm babies were 19.1% and 43.2% respectively. Fungal culture positivity among normal birth weight (NBW), low birth weight (LBW) and very low birth weight (VLBW) babies were 26.3%, 46.8% and 33.3% respectively. Of the 58 NAC species isolated, 3 were from neonates with early-onset sepsis and the rest 55 were from cases with late-onset sepsis. The ratio of isolation of NAC species in neonates of diabetic and non diabetic mother was 2:1. Table-2 shows that *C. tropicalis* was the predominant species (81.0%) followed by *C. parapsilosis* (12.1%), *C. auris* (5.2%) and *C. dubliniensis* (1.7%).

Susceptibility of NAC species to fluconazole, ketoconazole, itraconazole, clotrimazole and nystatin by disc diffusion method is shown in Table-3. Out of 58 NAC isolates, 96.6%, 84.5%, 13.8% and 43.1% were resistant to fluconazole, ketoconazole, itraconazole and clotrimazole respectively. Except one *C. parapsilosis* isolate, none was resistant to voriconazole. None of the isolated NAC species was resistant to miconazole and nystatin.

Table-1: Rate of isolation of NAC species and bacteria from different category of study population

Category of study population	Number of cases	Positive for		
		Bacteria n (%)	NAC species n (%)	Total n (%)
All cases	146	33 (22.6)	58 (39.7)	91 (62.3)
Male	99	19 (19.2)	49 (49.5)	68 (68.7)
Female	47	14 (29.8)	9 (19.2)	23 (48.9)
Term	21	1 (4.8)	4 (19.1)	5 (23.8)
Preterm	125	32 (25.6)	54 (43.2)	86 (68.8)
NBW	19	1 (5.3)	5 (26.3)	6 (31.6)
LBW	79	12 (15.2)	37 (46.8)	49 (62.0)
VLBW	48	20 (41.7)	16 (33.3)	36 (75.0)

Note: NBW – normal birth weight, LBW – low birth weight, VLBW – very low birth weight.

Table-2: Types of NAC species isolated from study population (n=58)

Candida species	Number (%)
<i>C. tropicalis</i>	47 (81.0)
<i>C. parapsilosis</i>	7 (12.1)
<i>C. auris</i>	3 (5.2)
<i>C. dubliniensis</i>	1(1.7)

Table-4 shows the resistance pattern of isolated NAC species to fluconazole, amphotericin B and anidulafungin by MIC method. Among the 47 *C. tropicalis*, 44 (93.6%) were resistant to fluconazole. *C. parapsilosis*, *C. auris* and *C. dubliniensis* were 100% resistant to fluconazole by both disc diffusion and MIC methods. All the *C. tropicalis*, *C. auris* and *C. dubliniensis* were sensitive to amphotericin B and anidulafungin. Out of 7 *C. parapsilosis*, 1

(14.3%) and 4 (57.1%) were found resistant to amphotericin B and anidulafungin respectively. The MIC results obtained by using RPMI 1640 and TSB as growth medium were concordant suggesting that TSB media could be a good alternative to expensive RPMI 1640.

Table-5 shows the MIC₅₀ and MIC₉₀ of fluconazole, amphotericin B and anidulafungin of isolated NAC species. MIC₅₀ value of fluconazole for all the NAC isolates were in the resistant range. MIC₅₀ of amphotericin B for *C. tropicalis*, *C. parapsilosis*, *C. auris* and *C. dubliniensis* were 0.5 µg/ml, 1 µg/ml, 1 µg/ml and 0.25 µg/ml respectively and these values were all within the sensitive range. Only MIC₉₀ of amphotericin B for *C. parapsilosis* was 2 µg/ml which was in the resistant range. MIC₅₀ of anidulafungin for *C. parapsilosis* was 4 µg/ml and was in the resistant range. Both MIC₅₀ and MIC₉₀ of

Table-3: Antifungal susceptibility pattern of the isolated NAC species by disk diffusion method

Organism	Number	Resistant n (%) to						
		Fluconazole	Voriconazole	Ketoconazole	Itraconazole	Miconazole	Clotrimazole	Nystatin
<i>C. tropicalis</i>	47	45 (95.7)	0	38 (80.9)	8 (17.0)	0	19 (40.4)	0
<i>C. parapsilosis</i>	7	7 (100)	1 (14.3)	7 (100)	0	0	6 (85.7)	0
<i>C. auris</i>	3	3 (100)	0	3 (100)	0	0	0	0
<i>C. dubliniensis</i>	1	1 (100)	0	1 (100)	0	0	0	0
Total	58	56 (96.6)	1 (1.7)	49 (84.5)	8 (13.8)	0	25 (43.1)	0

Table-4: Antifungal susceptibility pattern of isolated NAC species to fluconazole, amphotericin B and anidulafungin by MIC method

Candida sp.	Number	Resistant to		
		Fluconazole n (%)	Amphotericin B n (%)	Anidulafungin n (%)
<i>C. tropicalis</i>	47	44 (93.6)	0	0
<i>C. parapsilosis</i>	7	7 (100)	1 (14.3)	4 (57.1)
<i>C. auris</i>	3	3 (100)	0	0
<i>C. dubliniensis</i>	1	1 (100)	0	0

Table-5: MIC₅₀ and MIC₉₀ of fluconazole, amphotericin B and anidulafungin of isolated NAC species

<i>Candida</i> sp	Number	Fluconazole		Amphotericin B		Anidulafungin	
		MIC ₅₀	MIC ₉₀	MIC ₅₀	MIC ₉₀	MIC ₅₀	MIC ₉₀
<i>C. tropicalis</i>	47	32	32	0.5	1	0.032	0.032
<i>C. parapsilosis</i>	7	16	32	1	2	4	4
<i>C. auris</i>	3	32	32	1	1	0.032	0.032
<i>C. dubliniensis</i>	1	16	16	0.25	0.25	0.008	0.008

anidulafungin for rest of the *Candida* species were within the sensitive range. The lowest drug concentration required to inhibit the growth of 50% of organisms (MIC₅₀) and minimum concentration required to kill 50% of viable organisms (MFC₅₀) of the antifungal drugs for all the *Candida* species were calculated and shown in Table-6. MFC₅₀ was 2 fold higher than MIC₅₀ for fluconazole, amphotericin B and anidulafungin for all the NAC species.

Table-6: MIC₅₀ versus MFC₅₀ of fluconazole, amphotericin B and anidulafungin for all NAC species

Antifungal agents	MIC ₅₀ µg/ml	MFC ₅₀ µg/ml
Fluconazole	32	64
Amphotericin B	0.5	1
Anidulafungin	0.032	0.064

Discussion

The present study has for the first time demonstrated the distribution of different non-albicans *Candida* species responsible for sepsis among neonates admitted in the NICUs of different hospitals in Dhaka city. In the current study 39.7% neonates were culture positive for NAC species. ARTEMIS Antifungal Surveillance study conducted between June 1997 and December 2007 in 41 countries reported a declining trend in isolation of *C. albicans* from 70.9% to 65.9% [24]. A similar trend of emergence of NAC species in bloodstream infection has also been documented in a number of studies [25-31].

In this study, prematurity, LBW, VLBW, antibiotic prophylaxis and extended hospital stay could be the important reasons for high isolation of NAC

species. Long-term use of broad-spectrum antibiotics in routine empiric therapy also contributes to an overgrowth of opportunistic *Candida* by reducing the competitive pressure imparted by normal bacterial flora [32]. Also, increased use of azole antifungal agents, particularly fluconazole, leads to an increase in the distribution of NAC species and a decrease in *C. albicans* [33].

In our study, we also observed higher rate of fungal septicemia in neonates born to diabetic mothers than that of non-diabetic mothers (66.7% versus 22.5%; $p < 0.05$). Pregnant women with diabetes are at high risk of infection with *Candida* because the raised sugar promotes overgrowth of *Candida* and thus the neonates of the diabetic mothers are prone to be colonized with *Candida* from birth [34].

In the present study, among NAC species, *C. tropicalis* was the most common species (81.0%). Various other studies have also reported *C. tropicalis* to be the most common isolate [3,30,31]. Pressure of fluconazole prophylaxis could be the reason behind this high rate of isolation of *C. tropicalis* in this study.

The isolated NAC species were 98.3% sensitive to voriconazole and this finding is similar to the results published by other studies [35,36]. In the present study, resistant rate to fluconazole by the *Candida* isolates was 87.9% by disk diffusion and 94.8% by MIC method. All the *C. parapsilosis* and *C. auris* were resistant to fluconazole while *C. tropicalis* isolates were 93.6% resistant. These findings were in agreement with Pandita et al. and Yadav et al [37,38]. All the *C. tropicalis*, *C. auris* and *C. dubliniensis* were sensitive to amphotericin B and anidulafungin. Out of 7, only 1 (14.3%) *C. parapsilosis* was found resistant to amphotericin B and 4 (57.1%) were resistant to anidulafungin. Therefore, it appeared that amphotericin B and anidulafungin could be used against NAC species when the organisms become

resistant to other antifungal agents. There are only few literatures available regarding the use of echinocandin particularly anidulafungin in the pediatric ICU. Anidulafungin might be used as an alternative drug in neonates particularly when the local *Candida* strains are resistant to azoles. However, since the first introduction of echinocandins, these antifungal agents have exhibited higher minimum inhibitory concentrations against *C. parapsilosis*. Compared to other species of *Candida*, *C. parapsilosis* demonstrates higher *in vitro* MICs to echinocandin, and treatment failures with these antifungal agents have been reported for *C. parapsilosis* infections [39,40].

Antifungal susceptibility was done by disk-diffusion and MIC broth microdilution methods. RPMI 1640 is the proposed medium for carrying out micro broth dilution by EUCAST and NCCLs (M27-A2). However, RPMI 1640 is very expensive and not easily available in many laboratories. So, MIC of fluconazole and amphotericin B for *Candida* species were done using both TSB and RPMI 1640 medium and the results were compared. The MIC results obtained by both the media were concordant suggesting that TSB broth media could be a good alternative to RPMI 1640.

In our study, we observed the minimum fungicidal concentrations (MFC) of fluconazole, amphotericin B and anidulafungin as 2 fold higher than the MIC. Very little is known regarding the role of differences between MIC and MFC in treatment failure, and further studies are required.

The present study provided evidence of colossal burden of NAC species as an important cause of neonatal sepsis in our NICUs. The isolated NAC species were found highly resistant to widely used fluconazole whereas amphotericin B, voriconazole and anidulafungin were the most effective agents. The results of our study could be used as a template for the establishment of local guidelines for the effective treatment and prevention of neonatal candidemia.

Competing interest

The authors declared no competing interests.

Funding

None

References

1. Benjamin DK, Stoll BJ, Fanaroff AA, McDonald SA, Oh W, Higgins RD, et al. Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. *Pediatrics*. 2006; **117**(1): 84-92.
2. Oberoi JK, Wattal C, Goel N, Raveendran R, Datta S, Prasad K. Non-*albicans* *Candida* species in blood stream infections in a tertiary care hospital at New Delhi, India. *Indian J Med Res*. 2012; **136**(6): 997-1003.
3. Goel N, Ranjan PK, Aggarwal R, Chaudhary U, Sanjeev N. Emergence of non-*albicans* *Candida* in neonatal septicemia and antifungal susceptibility: experience from a tertiary care center. *J Lab Physicians*. 2009; **1**(2): 53-55.
4. Warris A. *Candida auris*, what do paediatricians need to know? *Arch Dis Child*. 2018; **103**(9): 891-894.
5. Singhi S, Rao DS, Chakrabarti A. *Candida* colonization and candidemia in a pediatric intensive care unit. *Pediatr Crit Care Med*. 2008; **9**(1): 91-95.
6. Rao S, Ali U. Systemic fungal infections in neonates. *J Postgrad Med*. 2005; **51** Suppl 1: S27-29.
7. Ariff S, Saleem AF, Soofi SB, Sajjad R. Clinical spectrum and outcomes of neonatal candidiasis in a tertiary care hospital in Karachi, Pakistan. *J Infect Dev Ctries*. 2011; **5**(03): 216-223.
8. Adib SM, Bared EE, Fanous R, Kyriacos S. Practices of Lebanese gynecologists regarding treatment of recurrent vulvovaginal candidiasis. *N Am Med Sci*. 2011; **3**(9): 406-410.
9. Sanglard D, Odds FC. Resistance of *Candida* species to antifungal agents: molecular mechanisms and clinical consequences. *Lancet Infect Dis*. 2002; **2**(2): 73-85.
10. Magill SS, Shields C, Sears CL, Choti M, Merz WG. Triazole cross-resistance among *Candida* spp.: case report, occurrence among bloodstream isolates, and implications for antifungal therapy. *J Clin Microbiol*. 2006; **44**(2): 529-535.

11. Cheesbrough M. District laboratory practice in tropical countries, part 2. Cambridge University Press; 2005.
12. Tarrand JJ, Guillot C, Wenglar M, Jackson J, Lajeunesse JD, Rolston KV. Clinical comparison of the resin-containing BACTEC 26 Plus and the Isolator 10 blood culturing systems. *J Clin Microbiol.* 1991; **29**(10): 2245-2249.
13. McGinnis MR. Laboratory handbook of medical mycology. Michigan: Michigan University Press; 1980. p. 661.
14. Land GA, Vinton EC, Adcock GB, Hopkins JM. Improved auxanographic method for yeast assimilations: a comparison with other approaches. *J Clin Microbiol.* 1975; **2**(3): 206-217.
15. Devadas SM, Ballal M, Prakash PY, Hande MH, Bhat GV, Mohandas V. Auxanographic carbohydrate assimilation method for large scale yeast identification. *J Clin Diagn Res.* 2017; **11**(4): DC01-DC03.
16. Welsh RM, Bentz ML, Shams A, Houston H, Lyons A, Rose LJ, et al. Survival, persistence, and isolation of the emerging multidrug-resistant pathogenic yeast *Candida auris* on a plastic health care surface. *J Clin Microbiol.* 2017; **55**(10): 2996-3005.
17. Clinical and Laboratory Standards Institute. Methods for antifungal disk diffusion susceptibility testing of yeasts; Approved Guideline M44-A, Vol. 24, Number 15. 2nd ed. Wayne, USA: Clinical and Laboratory Standards Institute; 2004.
18. Pam VK, Akpan JU, Oduyebo OO, Nwaokorie FO, Fowora MA, Oladele RO, et al. Fluconazole susceptibility and ERG11 gene expression in vaginal *Candida* species isolated from Lagos Nigeria. *Int J Mol Epidemiol Genet.* 2012; **3**(1): 84-90.
19. Dota KF, Freitas AR, Consolaro ME, Svidzinski TI. A challenge for clinical laboratories: detection of antifungal resistance in *Candida* species causing vulvovaginal candidiasis. *Lab Med.* 2011; **42**(2): 87-93.
20. Vandeputte P, Larcher G, Bergès T, Renier G, Chabasse D, Bouchara JP. Mechanisms of azole resistance in a clinical isolate of *Candida tropicalis*. *Antimicrob Agents Chemother.* 2005; **49**(11): 4608-4615.
21. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts M27-A2, Vol. 22, Number 15. 2nd ed. Wayne, USA: Clinical and Laboratory Standards Institute; 2002.
22. European Society of Clinical Microbiology and Infectious Diseases. Method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts. EUCAST Definitive Document E.DEF 7.3. Copenhagen: European Society of Clinical Microbiology and Infectious Diseases; 2015.
23. Torres-Rodríguez JM, Alvarado-Ramírez E, Murciano F, Sellart M. MICs and minimum fungicidal concentrations of posaconazole, voriconazole and fluconazole for *Cryptococcus neoformans* and *Cryptococcus gattii*. *J. Antimicrob Chemother.* 2008; **62**(1): 205-206.
24. Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Ellis D, Tullio V, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of *Candida* species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. *J Clin Microbiol.* 2010; **48**(4): 1366-1377.
25. Kossoff EH, Buescher ES, Karlowicz MG. Candidemia in a neonatal intensive care unit: trends during fifteen years and clinical features of 111 cases. *Pediatr Infect Dis J.* 1998; **17**(6): 504-508.
26. Sardana V, Pandey A, Madan M, Goel SP, Asthana AK. Neonatal candidemia: a changing trend. *Indian J Pathol Microbiol.* 2012; **55**(1): 132-133.
27. Rani R, Mohapatra NP, Mehta G, Randhawa VS. Changing trends of *Candida* species in neonatal septicaemia in a tertiary North Indian hospital. *Indian J Med Microbiol.* 2002; **20**(1): 42-44.
28. Femitha P, Joy R, Adhisivam B, Bhat V, Prasad K, Gane BD, Singh R. Candidemia in neonatal ICU-experience from a tertiary care hospital. *Skin.* 2013; **5**: 13-19.
29. Shrivastava G, Bajpai T, Bhatambare GS, Chitnis V, Deshmukh AB. Neonatal candidemia: Clinical

- importance of species identification. *Sifa Med J*. 2015; **2**(2): 37.
30. Capoor MR, Nair D, Deb M, Verma PK, Srivastava L, Aggarwal P. Emergence of non-*albicans Candida* species and antifungal resistance in a tertiary care hospital. *Jpn J Infect Dis*. 2005; **58**(6): 344-348.
31. Agarwal J, Bansal S, Malik GK, Jain A. Trends in neonatal septicemia: emergence of non-*albicans Candida*. *Indian pediatrics*. 2004; **41**(7): 712-715.
32. Benjamin DK, Stoll BJ, Gantz MG, Walsh MC, Sánchez PJ, Das A, et al. Neonatal candidiasis: epidemiology, risk factors, and clinical judgment. *Pediatrics*. 2010; **126**(4): e865-e873.
33. Filioti J, Spiroglou K, Roilides E. Invasive candidiasis in pediatric intensive care patients: epidemiology, risk factors, management, and outcome. *Intensive Care Med*. 2007; **33**(7): 1272-1283.
34. Sopian IL, Sa'adiah Shahabudin MA, Lung LT, Sandai D. Yeast infection and diabetes mellitus among pregnant mother in Malaysia. *Malays J Med Sci*. 2016; **23**(1): 27-34.
35. Kavitha H, Anuradha K, Venkatesha D. Comparison of susceptibility of various *Candida* species isolated from neonatal septicaemia to voriconazole and fluconazole. *IOSR J Pharm Biol Sci*. 2014; **9**(02): 78-81.
36. Nazir A. Non-*albicans Candida* in neonatal septicemia: an emerging clinical entity. *Int J Biomed Res*. 2016; **7**(2): 47-50.
37. Pandita N, Peshin C, Wasim S, Bhat NK, Gupta A. Profile of fungal septicaemia in new born at a tertiary care hospital in North India. *Int J Contemp Pediatr*. 2017; **4**(2): 455-459.
38. Yadav S, Dahiya S, Budhani D. Candidemia in neonatal intensive care unit: a cause of concern. *Int J Res Med Sci*. 2017; **5**(5): 2165-2167.
39. Arendrup MC, Perlin DS. Echinocandin resistance: an emerging clinical problem? *Curr Opin Infect Dis*. 2014; **27**(6): 484-492.
40. Perlin DS. Echinocandin resistance, susceptibility testing and prophylaxis: implications for patient management. *Drugs*. 2014; **74**(14): 1573-1585.